Roche Holding stock: Deutsche Bank sets CHF 500 target for Roche Holding stock

Published on 10/23/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales rose 6.00 percent to CHF 46.5 billion. Roche Holding stock costs EUR 422.88 on October 23, 2026, down 0.50 percent versus the Tradegate close.

Deutsche Bank target raised

Deutsche Bank raised its Roche target from CHF 340.00 to CHF 500.00 on October 23, 2026.
Roche reported first-nine-month sales growth of 6.00 percent at constant exchange rates.
Roche Holding stock costs EUR 422.88 at Lang & Schwarz on October 23, 2026 at 4:42 p.m. CEST, 0.50 percent below the Tradegate close of October 22, 2026.
Roche listed November 30, 2026 and December 18, 2026 as FDA decision dates for Giredestrant.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Deutsche Bank Research raised its Roche target from CHF 340.00 to CHF 500.00 and upgraded the shares from Hold to Buy on October 23, 2026, citing physician feedback on Giredestrant in an oncology survey, Deutsche Boerse reported. Roche Holding stock was at EUR 422.88 at Lang & Schwarz on October 23, 2026 at 4:42 p.m. CEST, down 0.50 percent versus the Tradegate close of October 22, 2026 at EUR 425.00.

Sales provide the operating backdrop

Roche's third-quarter sales increased 7.00 percent at constant exchange rates and 8.00 percent in Swiss francs, while sales for the first nine months of 2026 rose 6.00 percent at constant exchange rates and 1.00 percent in Swiss francs. The company said the growth came from demand for innovative medicines and diagnostics in its release dated October 22, 2026, carried by FinanzNachrichten. Pharma sales rose 7.00 percent at constant exchange rates to CHF 36.2 billion in the first nine months, while Diagnostics sales rose 4.00 percent to CHF 10.3 billion.

The Swiss quote remains below the target

Roche shares closed at CHF 392.10 on the SIX on October 22, 2026. Deutsche Bank's CHF 500.00 target therefore stood 27.55 percent above that Swiss closing price, a comparison that uses the same currency and the analyst note dated October 23, 2026.

Two regulatory dates follow

Roche's October 22, 2026 release listed November 30, 2026 as the FDA decision date for Giredestrant in early-stage breast cancer and December 18, 2026 for advanced breast cancer. The same release said Roche confirmed its full-year 2026 outlook, targeting mid-single-digit group sales growth at constant exchange rates and high-single-digit core earnings-per-share growth.

Pipeline breadth shapes the comparison

The sales mix gives investors a useful counterweight to the target increase. Roche's five leading medicines generated CHF 16.8 billion in the first nine months of 2026, up 12.00 percent at constant exchange rates, while products with expired patents declined by CHF 0.4 billion at constant exchange rates. Diagnostics added a second growth stream, although its sales were flat in Swiss francs during the period.

Roche stock and the next dates

The analyst action puts more weight on pipeline execution than on the small euro-quote move. Roche's confirmed outlook and the two Giredestrant decision dates provide the next company-specific markers after the October 22, 2026 sales update.

Price stays below the Tradegate close

Roche Holding stock was trading at EUR 422.88 at Lang & Schwarz on October 23, 2026 at 4:42 p.m. CEST, 0.50 percent below the Tradegate close of October 22, 2026 at EUR 425.00. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.